Relapsing Multiple Sclerosis (RMS) Clinical Trial
Official title:
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 [NCT03277261]) or TG1101-RMS302 (RMS302 [NCT03277248]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E [NCT03381170]) (United States of America [USA] participants only). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277261 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
|
Phase 3 | |
| Completed |
NCT02921035 -
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
|
||
| Completed |
NCT04878211 -
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
Phase 4 | |
| Recruiting |
NCT04086225 -
Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®
|
Phase 1 | |
| Completed |
NCT03745144 -
Effects of Cladribine Tablets on the PK of Microgynon®
|
Phase 1 | |
| Active, not recruiting |
NCT04667949 -
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
|
Phase 4 | |
| Completed |
NCT03277248 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 |